**Abstract**

Retinoid-related orphan receptor γt (RORγt) is known to be related to the development and function of various immunological compartments in the liver, such as Th17 cells, natural killer T (NKT) cells, and innate lymphoid cells (ILCs). We evaluated the roles of RORγt-expressing cells in mouse acute hepatitis model using RORγt-deficient (RORγt−/−) mice and RAG-2 and RORγt double deficient (RAG-2−/− × RORγt−/−) mice. Acute hepatitis was induced in mice by injection with carbon tetrachloride (CCL4) to investigate the regulation of liver inflammation by RORγt-expressing cells. We detected RORC expression in three compartments, CD4+ T cells, NKT cells, and lineage marker-negative SCA-1+Thy1high ILCs, of the liver of wild type (WT) mice. CCL4-treated RORγt−/− mice developed liver damage in spite of lack of RORγt-dependent cells, but with reduced infiltration of macrophages compared with WT mice. In this regard, ILCs were significantly decreased in RAG-2−/− × RORγt−/− mice that lacked T and NKT cells. Surprisingly, RAG-2−/− × RORγt−/− mice developed significantly severer CCL4-induced hepatitis compared with RAG-2−/− mice, in accordance with the fact that hepatic ILCs failed to produce IL-22. Lastly, anti-Thy1 monoclonal antibody (mAb), but not anti-NK1.1 mAb or anti-asialo GM1 Ab administration exacerbated liver damage in RAG-2−/− mice with the depletion of liver ILCs. Collectively, hepatic RORγt-dependent ILCs play a part of protective roles in hepatic immune response in mice.

**Introduction**

Retinoid-related orphan receptor γt (RORγt) is a transcription factor that regulates a variety of immunological processes [1–3] and has an indispensable role in the development of Th17 cells [1]. Activated Th17 cells secrete a variety of IL-17 family cytokines including IL-17A, IL-21, and IL-22, which promotes tissue inflammation by induction of other proinflammatory mediators and the recruitment of leukocytes to sites of inflammation [4]. Among IL-17 family cytokines, the role of IL-22 in inflammatory responses is unclear owing to contrary data suggesting pro- or anti-inflammatory functions in distinct tissues [5–9]. However, during the pathogenesis of acute hepatitis models, IL-22 produced by Th17 cells is thought to have a protective role by preventing tissue injury [7–9].

The development of all T cells and NKT cells depend on RORγt to some extent, as it is expressed by CD4+ and CD8+ double positive thymocytes [10,11]. Con A-induced acute hepatitis is a lymphocyte-mediated hepatitis model in rodents [12], largely dependent on NKT cell secretion of IFN-γ, TNF-α, and IL-4 [13–16].

Furthermore, RORγt is essential for generation of lymphoid tissue inducer (LTI) cells, which are critically involved in the development of secondary lymphoid tissues, such as lymph nodes, Peyer’s patches, and cryptopatches [3]. Recent studies reported that various subtypes of RORγt+ innate lymphoid cells (ILCs), including LTi cells, producing IL-17A, IL-22 and/or IFN-γ have various roles in innate immune responses, lymphoid tissue formation, and tissue remodeling [2,17].

Although the roles of RORγt-dependent Th17 cells or NKT cells in the development of murine acute hepatitis models have been clarified, those of RORγt-dependent ILCs have not been investigated. To clarify the roles of RORγt-dependent ILCs in the development of acute hepatitis, we induced CCL4-hepatitis in RORγt−/− and RORγt−/− × RAG-2−/− mice.

**Materials and Methods**

**Mice**

Eight- to 12-wk-old C57BL/6 (WT) mice were purchased from Japan CLEA (Tokyo, Japan). C57BL/6 background RAG-2-deficient mice were obtained from Central Laboratories for Experimental Animals (Kawasaki, Japan). Mice with green fluorescent protein reporter complementary DNA knocked-in at the site for initiation of RORγt translation on the C57BL/6 background were purchased from Japan CLEA (Tokyo, Japan).
background (ROR$\gamma^-$) were kindly provided by Dr. D. Litman [18]. RAG-2$^{-/-} \times$ ROR$\gamma^-$ mice were obtained by crossing RAG-2$^{-/-}$ mice with ROR$\gamma^-$ mice. Mice were maintained under specific pathogen-free conditions in the Animal Care Facility of Keio University School of Medicine. This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of Keio University School of Medicine. All surgery was performed under anesthesia, and all efforts were made to minimize suffering.

Preparation of hepatic mononuclear cells

Hepatic mononuclear cells (MNCs) were isolated from the liver as described previously [19]. Briefly, livers were perfused through the portal vein with PBS, then minced and passed through nylon mesh. The filtrate was centrifuged at 50×g for 50 seconds and supernatant was collected and centrifuged. Cells were suspended in a Hanks’ balance salt solution and overlaid on a Histopaque solution (Sigma-Aldrich, St. Louis, MO, USA). After centrifugation at 2000 rpm for 20 minutes, the cells were collected from the upper layer of the Histopaque.

Induction of CCl4 and α-galactosylceramide (αGalCer) hepatitis models

CCl4 was purchased from Wako (Osaka, Japan). CCl4 (0.75 ml/kg) in olive oil was injected intraperitoneally in each mouse. In some CCl4-induced hepatitis experiments, mice were injected 12 hours before examination.

Measurement of liver injury

Serum ALT levels were measured using the LDH-UV kinetic method (SRL Inc., Tokyo, Japan). Livers were fixed in 10% formalin and embedded in paraffin. Sections were stained with H&E and examined. Statistic evaluation was performed by using pathologic score referring to the previous report [20]. Briefly, the overall degree or grade of necrosis was scored from 0 to 4 on the basis of the severity and distribution of the necrotic lesions and the number of lobes affected as follows: 0–None, 1–Minimal to Mild, 2–Moderate, 3–Marked, 4–Severe to Diffuse.

Flow cytometric analysis and cell sorting

Flow cytometric analysis was performed as described previously [19]. Briefly, after blocking with anti-FcR (CD16/32, BD Pharmingen, San Jose, CA, USA) for 15 minutes, the cells were incubated with fluorescence-labeled mAb at 4°C for 20 minutes. For intracellular staining, cells were stimulated for 3 h with mouse recombinant IL-23 (40 ng/mL, R&D Systems, Minneapolis, MN, USA); for the final 1.5 h, GolgiPlug (BD Pharmingen) was added. After surface staining, the cells were resuspended in Fixation/Permeabilization solution (BD Pharmingen), and intracellular staining was performed. In terms of intracellular staining for transcriptional factor, Fixation/Permeabilization Concentrate (eBioscience) was used, and intracellular staining was performed without stimulation. The following mAbs were used: anti-CD11b (FTC and PE), anti-CD11c (PE-Cy7), anti-B220 (FITC), anti-Gr-1 (FITC), anti-IL-22 (PE), anti-IL-17A (PE), anti-IFN-γ (PE), anti-NKp46 (PE), anti-IL-7R (Biotin), anti-TCRβ (APC), anti-NK1.1 (PE), anti-SCA1 (PE-Cy7), anti-Thy1 (APC-Cy7), anti-c-kit (PE), anti-CD25 (PE), anti-CD44 (APC), anti-CCR6 (APC), anti-RORγt (PE), Streptavidin (PE) and 7-AAD from eBioscience (San Diego, CA, USA); BD Pharmingen, and BioLegend (San Diego, CA, USA). The stained cells were analyzed on FACS Canto II (BD) and the data were analyzed using FlowJo software (Tree Star Inc.). Cell sorting was performed on FACS AriaTM to obtain a pure population.

RT-qPCR

RNA was extracted from liver tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Complementary DNA was synthesized from extracted RNA using TaqMan® Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). Reverse transcription was performed at 25°C for 10 min, 48°C for 30 min, and then 95°C for 5 min. Complementary DNA was analyzed by RT-qPCR using TaqMan® Universal PCR Master Mix (Applied Biosystems) in Applied Biosystems StepOneTM/StepOnePlusTM (Applied Biosystems). The following probes were purchased from Applied Biosystems: Il22 (Mm00444241_m1), Il6 (Mm00446190_m1), Tnf (Mm00999068_m1), Rorc (Mm01261022_m1) and mouse β-actin. Relative quantification was achieved by normalizing to the value of the β-actin gene.

Statistical analysis

The results were expressed as the mean ± standard error of mean (SEM). Groups of data were compared using the Student’s t-test. In terms of the evaluating pathological score, data compared using the Mann-Whitney test. Differences were considered to be statistically significant when p<0.05. ***p<0.001, **p<0.01, *p<0.05, NS, not significantly different.

Results

CD4+ T cells, NKT Cells and ILCs in the Liver Expressed RORγt, and ILCs Were Decreased in RAG-2$^{-/-}$ × RORγt$^{-/-}$ mice

To determine the expression of RORγt in the liver of normal mice, we isolated the following MNC subsets: CD11b+TCRβ- macrophages, CD11c+TCRβ+ dendritic cells (DCs), CD4+TCRβ+ CD4 T cells, CD8+TCRβ+ CD8 T cells, NK1.1+TCRβ- NK cells, NK1.1+TCRβ+ NKT cells, and Lin-SCA-1+Thy1high ILCs, and evaluated the level of RORC expression by RT-qPCR. To obtain ILCs from the liver, we used anti-CD3e mAb in addition to the lineage markers [2], to further exclude T and NKT cells. Thus, using the isolated liver cell populations we detected the expression of RORγt in CD4 T cells, NKT cells, and ILCs, and observed the expression of RORγt in ILCs was much higher than in CD4 T cells and NKT cells (Fig. 1A).

We also investigated the frequency of hepatic Lin+ ILCs. Since T cells are present in the Lin–SCA-1+Thy1high population (data not shown), we compared lymphocyte-lacking RAG-2$^{-/-}$ mice with RAG-2$^{-/-}$ × RORγt$^{-/-}$ mice to exclude the possibility of T cell contamination. Consequently, the frequency of hepatic ILCs in RAG-2$^{-/-}$ × RORγt$^{-/-}$ mice was also significantly reduced compared with RAG-2$^{-/-}$ mice (Fig. 1B and 1C). The ILCs expressed IL-7R, CD25, CD44 and CCR6, but not NK1.1, NKp46 and c-kit (Fig. 1D), suggesting that ILCs in the liver had similar characteristics to ILCs in the intestine [2]. Furthermore,
almost all of SCA-1^{+}Thy1^{high} hepatic ILCs expressed RORγt (Fig. 1D).

**RORγt^{−/−} Mice Develop Carbon Tetrachloride (CCl4)-induced Acute Hepatitis**

To assess the role of RORγt dependent cells including NKT cells, Th17 cells and hepatic RORγt^{+} ILCs in hepatitis, we used a carbon tetrachloride (CCl4)-induced hepatitis model in WT and RORγt^{−/−} mice. CCl4 administration directly damages hepatocytes and induces hepatitis. [21] IL-22 produced by Th17 cells has effect on the existence of some RORγt-dependent protective cells besides RORγt-dependent pathological NKT cells in this model.

**RORγt Deficiency in RAG-2^{−/−} Mice Exacerbates CCl4-induced Hepatitis**

To investigate the function of RORγt-dependent hepatic ILCs without the impact of NKT and Th17 cells, we investigated the effect of RORγt^{−/−} mice on the development of hepatitis. In this regard, it is notable that Buonocore et al. reported that Lin^{−} SCA-1^{−}Thy1^{high} ILCs producing IL-22 reside in Helicobacter hepatus-infected liver [2]. Furthermore, Zenewicz et al. previously reported that Con A-induced hepatitis was exacerbated in IL-22 deficient mice, but they emphasized the importance of T cells including Th17 cells as the source of IL-22 in that model [9]. The frequency of Lin^{−} SCA-1^{−}Thy1^{high} ILCs was significantly lower in RAG-2^{−/−} x RORγt^{−/−} mice after olive oil or CCl4 injection, but there was no difference in the number of ILCs after CCl4 injection, as the absolute cell numbers of MNCs were markedly increased in CCl4-administered RAG-2^{−/−} x RORγt^{−/−} mice compared with RAG-2^{−/−} mice. Unlike NKT cell-dependent hepatic ILCs in RORγt^{−/−} mice, although they lack Th17 cells owing to the increased severity of disease (Fig. 3E). Interestingly, IL-22 mRNA was detectable only in the hepatic MNCs of CCl4-injected RAG-2^{−/−} x RORγt^{−/−} mice, but not RAG-2^{−/−} x RORγt^{−/−} mice, although they lack Th17 cells (Fig. 3F). Furthermore, the expression of TNF-α mRNA in hepatic MNCs was significantly increased in CCl4-injected RAG-2^{−/−} x RORγt^{−/−} mice compared with CCl4-injected RAG-2^{−/−} mice (Fig. 3F). In addition, exogenous IL-22 injection protected RAG-2^{−/−} x RORγt^{−/−} mice from CCl4-induced hepatitis to some extent (Fig. S2).
Hepatic RORγt+ ILCs Are the Main Source of IL-22 Production in CCl4-induced Hepatitis in Mice

To evaluate the function of hepatic ILCs in the CCl4 hepatitis model, we isolated the following MNC subsets 12 h following CCl4 administration: Lin−SCA-1+Thy1high ILCs, Lin−Thy1− cells, Lin+ cells, and evaluated the level of IL-22 expression by RT-qPCR. As shown in Fig. 4A, only Lin−SCA-1+Thy1high ILCs expressed IL-22 after CCl4 administration. Furthermore, to investigate cytokines production in vitro condition, hepatic MNCs collected from CCl4-injected RORγt−/− mice were stimulated with or without IL-23. As the result, fluorescence-activated cell sorter analysis revealed that Lin−SCA-1+Thy1high ILCs from CCl4-injected RORγt−/− mice produced IL-22, IL-17A, and IFN-γ upon IL-23 simulation, but those from CCl4-injected RORγt+/− mice did not (Fig. 4B). The absence of IL-22 production from hepatic ILCs of CCl4-injected RORγt−/− mice in vitro was consistent with the result of RT-qPCR analysis of hepatic MNCs isolated from CCl4-injected RORγt−/− mice (Fig. 4F).

Hepatic RORγt+ ILCs Are Different from Conventional NK cells which Aren’t Related to the Development of CCl4-induced Hepatitis

To further evaluate the possible involvement of NK cells in this model of CCl4-induced hepatitis, anti-asialo GM1 Ab was administered to RAG-2−/− × RORγt−/− mice 1 day and 3 hours prior to before CCl4-injection to deplete conventional NK cells. As the result, there was no difference between PBS treated- and anti-asialo GM1 Ab treated- RAG-2−/− mice as to not only the level of

Figure 2. RORγt−/− mice develop CCl4-induced hepatitis. (A) Serum ALT levels of WT or RORγt−/− mice 12 h after CCl4 (WT n = 5, RORγt−/− n = 4) or olive oil injection (n = 5/group). Data show the mean ± SEM. (B) Representative photomicrographs of H&E-stained liver from each group and pathological score. (C) CD11b/CD11c staining of hepatic MNCs from WT or RORγt−/− mice 12 h after CCl4 or olive oil treatment. Ratio and absolute number of CD11b+ macrophages in the hepatic MNCs. Data show the mean ± SEM. (D) TCRβ/NK1.1 staining of hepatic MNCs. Ratio and absolute number of NKT cells in the hepatic MNCs. Data show the mean ± SEM. Data are representative of two independent experiments.
doi:10.1371/journal.pone.0062853.g002
Figure 3. RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> mice develop more severe CCl4-induced hepatitis than RAG-2<sup>-/-</sup> mice. (A) Serum ALT levels of RAG-2<sup>-/-</sup> or RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> mice 12 h after CCl4 (RAG-2<sup>-/-</sup> n = 9, RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> n = 8) or olive oil injection (n = 8/group). Data show the mean ± SEM. (B) Representative photomicrographs of H&E-stained liver from each group and pathological score. (C) CD11b/CD11c staining of hepatic MNCs from RAG-2<sup>-/-</sup> or RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> mice 12 h after CCl4 (RAG-2<sup>-/-</sup> n = 5, RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> n = 4) or olive oil treatment (n = 5/group). Ratio and absolute number of CD11b<sup>+</sup> macrophages in the hepatic MNCs. Data show the mean ± SEM. (D) TCRβ/NK1.1 staining of hepatic MNCs. Ratio and absolute number of NK cells in the hepatic MNCs. Data show the mean ± SEM. (E) SCA-1/Thy1 staining of Lin<sup>-</sup> hepatic MNCs. Ratio of ILCs in Lin<sup>-</sup> fraction and absolute number of ILCs. (F) Cytokine mRNA expression in the hepatic MNCs from CCl4-injected RAG-2<sup>-/-</sup> or RAG-2<sup>-/-</sup> x RORγt<sup>-/-</sup> mice 12 h after CCl4 injection was determined by RT-qPCR. Data show the mean ± SEM Cytokine mRNA expression in the
serum ALT, but also the degree of histological liver injury (Fig. 5A and 5B). Absolute cell number of macrophages was also not significantly affected by the anti-asialo GM1 Ab treatment (Fig. 5D), although NK cells were efficiently depleted (Fig. 5E), indicating that NK cells are not essential for the development of this model. Furthermore, the injection of anti-asialo GM1 Ab did not deplete hepatic \( \text{ROR}^{\gamma c} \text{ILCs} \) (Fig. 5E). This result suggested that hepatic \( \text{ROR}^{\gamma c} \text{ILCs} \) are different cell population from NK cells.

Anti-Thy1, but not Anti-NK1.1, mAb Treatment Depletes Hepatic ILCs and Exacerbates CCl4-induced Hepatitis

To confirm the novel protective role of \( \text{ROR}^{\gamma c} \)-expressing ILCs in the CCl4 hepatitis model, RAG-2\(^{−/−}\) mice were treated with anti-Thy1 mAb or anti-NK1.1 mAb to deplete ILCs, as previously shown in murine models of acute colitis [22], and then administered CCl4. As shown in Fig. 6A, CCH-induced serum ALT levels were markedly increased by the anti-Thy1 mAb treatment, but not the anti-NK1.1 mAb treatment. This was concordant with the histological extent of liver damage (Fig. 6B), and an increase in the rate and absolute cell number of macrophages in the liver of anti-Thy1 mAb-treated RAG-2\(^{−/−}\) mice (Fig. 6C). Although anti-NK1.1 mAb-treated RAG-2\(^{−/−}\) mice had a higher frequency of macrophages, owing to NK cell depletion, there was no difference in the absolute cell numbers among these groups (Fig. 6C). We confirmed that anti-NK1.1 mAb effectively depleted almost all NK cells in the liver, while anti-Thy1 mAb substantially but not completely depleted NK cells (Fig. 6D). Furthermore, in sharp contrast to anti-NK1.1 mAb treatment, ILCs were completely depleted by anti-Thy1 mAb treatment, whereas anti-NK1.1 mAb treatment increased the relative ratio and absolute cell number of ILCs (Fig. 6E). The effects of anti-NK1.1 mAb treatment in RAG2\(^{−/−}\) mice were consistent with those of anti-asialo GM1 Ab that depletes conventional NK cells (Fig. 5).

**Discussion**

The current study demonstrated that \( \text{ROR}^{\gamma c} \)-dependent hepatic ILCs played a protective role on murine acute liver injury.
in IL-22 dependent manner. Fig. 7 gives a schematic view of the proposed roles of RORγt-dependent hepatic ILCs in acute hepatitis models revealed in this study.

Previous reports have demonstrated the importance of RORγt-dependent cells in various immune responses, as RORγt is essential for the development of lymphoid tissues and innate and adaptive immune cells such as Th17 cells, invariant or IL-17A producing NKT cells and ILCs [1,2,10,11,17,23]. To investigate the roles of RORγt-dependent cells in the liver, we focused on RORγt expression in hepatic MNCs subsets. We found that hepatic ILCs highly expressed RORγt in addition to CD4+ T cells and NKT cells, and the number of hepatic ILC cells was considerably decreased in the liver of RAG-2−/− × RORγt−/− mice. This suggests the possibility that RORγt-dependent hepatic ILCs are involved in hepatic immune responses. Notably, previous reports have emphasized that IL-22 produced by Th17 cells can act protectively in various acute hepatitis models, although NKT cells are pathogenic in the development of Con A-induced hepatitis [13,16]. Furthermore, we found that stimulated NKT cells induced the accumulation of inflammatory macrophages in the liver.

To investigate the roles of RORγt-dependent cells in the pathogenesis of acute liver injury, we first performed CCL4−/− mice in the hepatic MNCs fraction and absolute number of ILCs. Data show the mean ± SEM. Data are representative of two independent experiments.

doi:10.1371/journal.pone.0062853.g005

Figure 5. Anti-asialo GM1 Ab treatment does not affect the degree of CCL4-induced hepatitis or number of hepatic ILCs. (A) Serum ALT levels of olive oil- or CCL4-injected RAG-2−/− mice, or anti-asialo GM1 Ab and CCL4 (asialo GM1 CCL4) treated RAG-2−/− mice 12 h after CCL4 or olive oil injection. Data show the mean ± SEM (n = 5/group). (B) Representative photomicrographs of H&E-stained liver from each group and pathological score. (C) CD11b/CD11c staining of hepatic MNCs from each group 12 h after CCL4 or olive oil treatment. Ratio and absolute number of CD11b+ macrophages in the hepatic MNCs. Data show the mean ± SEM. (D) TCRβ/NK1.1 staining of hepatic MNCs. Ratio and absolute number of NK cells in the hepatic MNCs. Data show the mean ± SEM. (E) SCA-1/Thy1 staining of Lin− hepatic MNCs. Ratio of ILCs in the Lin− fraction and absolute number of ILCs. Data show the mean ± SEM. Data are representative of two independent experiments.
Figure 6. Depletion of ILCs with anti Thy-1 mAb exacerbates CCl4-induced hepatitis in RAG-2^{-/-} mice. (A) Serum ALT levels of olive oil or CCl4-injected RAG-2^{-/-} mice, or anti-Thy1 mAb and CCl4 (Thy1 CCl4) or anti-NK1.1 mAb and CCl4 (NK1.1 CCl4)-treated RAG-2^{-/-} mice 12 h after CCl4 or olive oil injection. Data show the mean ± SEM (n = 9/group). (B) Representative photomicrographs of H&E-stained liver from each group and pathological score. (C) CD11b/CD11c staining of hepatic MNCs from each group 12 h after CCl4 or olive oil treatment. Ratio and absolute number of CD11b^{+} macrophage in the hepatic MNCs. Data show the mean ± SEM (n = 5/group). (D) TCRb/NK1.1 staining of hepatic MNCs. Ratio and absolute number of NK cells in the hepatic MNCs. Data show the mean ± SEM (E) SCA-1/Thy1 staining of Lin^{-} hepatic MNC. Ratio of ILCs in the Lin^{-} fraction and absolute number of ILCs in each group. Data show the mean ± SEM. Data are representative of three independent experiments.

doi:10.1371/journal.pone.0062853.g006
immune cells keep a delicate balance in this model. As a candidate of RORγt-dependent protective cells, we focused on hepatic ILCs that highly express RORγt. In this regard, the Lin− SCA-1−Thy1+ high ILC subset expressing IL-17A, IFN-γ, and IL-22 was shown to reside in the liver of H. hepaticus-infected mice, but their functional roles were not determined [2,22]. We identified the existence of these hepatic cells also in the normal condition without H. hepaticus-infection, and clarified that they have a similar feature with previously reported intestinal ILCs as to the expression of some surface markers [2]. We next performed CCl4-induced acute hepatitis model using RORγt−/− and RAG-2−/− × RORγt−/− mice to investigate the roles of RORγt-dependent cells in the liver except Th17 cells and NKT cells. As expected, CCl4-administered RAG2−/− × RORγt−/− mice showed a severer hepatitis compared with CCl4-administered RAG-2−/− mice. Interestingly, hepatic MNCs from CCl4-treated RAG-2−/− × RORγt−/− mice consistently expressed IL-22, although they lack Th17 cells previously known as the source of IL-22 in the development of murine acute hepatitis models [7,9]. On the other hand, hepatic MNCs from CCl4-treated RAG-2−/− × RORγt−/− mice lacked IL-22 expression. Supporting these results, only Lin− SCA-1−Thy1+ high hepatic ILCs expressed IL-22 in the liver of CCl4-treated RAG-2−/− × RORγt−/− mice, but not those from CCl4-treated RAG-2−/− × RORγt−/− mice, produced IL-22 in response to IL-23 in vitro. Furthermore, the number of RORγt+ hepatic ILCs was also decreased, and exogenous IL-22 administration protected RAG-2−/− × RORγt−/− mice from hepatitis. This suggests a novel protective function of IL-22-expressing hepatic ILCs against acute liver injury. This was also confirmed using depleting mAbs. Hepatic RORγt+ ILCs were depleted by anti-Thy1 mAb, but not by anti-NK1.1 mAb or anti-asialo GM1 Ab, in the liver of CCl4-administered RAG-2−/− mice causing a severer hepatitis. These results indicated that hepatic RORγt+ ILCs are different from conventional NK cells and act protectively against liver injury. Although hepatic RORγt+ ILCs produce IFN-γ which is one of the pathological factors in CCH-induced hepatitis, [24] that function of hepatic RORγt+ ILCs seems to be not critical for the development of hepatitis since there was no difference between the livers from CCl4-administered RAG-2−/− mice and RAG-2−/− × RORγt−/− mice in terms of the expression of IFN-γ.

We also noticed that RAG-2−/− × RORγt−/− mice developed severer hepatitis following CCl4 administration when compared with RORγt−/− mice. These results may indicate that other tissue-protective cell subsets in B cells, T cells and/or NKT cells can ameliorate CCL4-induced tissue damage, although further study is needed to address this issue in the future.

The functions of some hepatic immunocompetent cells, such as T cells, NKT cells and macrophages have been believed to include defense against microbial pathogens or viral infection in the liver, [25–27] but can also inhibit the growth of cancer [28]. These cells mediate these functions by secreting inflammatory cytokines, like IFN-γ and TNF-α, to induce cytotoxicity in infected cells and tumor cells [25–28]. Accordingly, those inflammatory cells also induce liver injury when activated excessively, and cause acute hepatitis as shown in some murine acute hepatitis models [19,29]. IL-22 produced by RORγt+ hepatic ILCs may counteract inflammatory cells-mediated liver injury because IL-22 is a survival factor for hepatocytes by preventing and repairing liver damage [7]. RORγt is critically involved in the development and function of hepatic RORγt+ ILCs, also is important for Th17 cell development [1,2,4,10,11,17], thus Th17 cells may also play a role in the pathogenesis of liver inflammation, although this is still controversial [9,30,31]. However, as to the source of IL-22, Th17 cells certainly have a protective role against liver injury [9,23]. Although hepatic RORγt+ ILCs also have an ability to produce IL-22, hepatic RORγt+ ILCs may be able to act at an early innate immune response stage of liver injury compared with Th17 cells since they exist also in the naive condition.

We conclude that RORγt+ hepatic ILCs have a pivotal protective function against liver injury via IL-22 production. Therefore, RORγt+ hepatic ILCs may be involved in clinical hepatitis and represent a candidate for a target of novel treatment for clinical hepatitis since IL-22 can prevent and repair liver damage.

Supporting Information

Figure S1 RORγt−/− mice are resistant to αGalCer-induced hepatitis. (A) Serum ALT levels of WT or RORγt−/− mice 12 h after αGalCer or PBS injection. Data show the mean ± SEM (n = 5/group). (B) Representative photomicrographs of H&E-stained sections of the liver from each group. (C) CD11b+/CD11c+ staining of hepatic MNCs from WT or RORγt−/− mice 12 h after αGalCer or PBS injection. Ratio and absolute number of CD11b+ macrophage in the hepatic MNCs. Data show the mean ± SEM (n = 5/group). (D) TCRβ and NK1.1 staining of hepatic MNCs. Percentage and absolute number of NKT cells in the hepatic MNCs. Data show the mean ± SEM (n = 5/group). Data are representative of four independent experiments. (TIF)

Figure S2 Exogenous IL-22 administration protects RAG-2−/− × RORγt−/− mice from CCl4-induced hepatitis. (A) Serum ALT levels of RAG-2−/− × RORγt−/− mice 12 h after CCl4 or IL-22 and CCl4 injection (n = 7/group). Data show the mean ± SEM. (B) Representative photomicrographs of H&E-stained liver from each group and pathological score. (C) CD11b+/CD11c+ staining of hepatic MNCs from RAG-2−/− × RORγt−/− mice 12 h after CCl4 or IL-22 and CCl4 treatment. Ratio and absolute number of CD11b+ macrophages in the hepatic MNCs. Data show the mean ± SEM. Data are representative of two independent experiments. (TIF)
Acknowledgments

We thank Dr. Li for helping perform experiments, and Dr. Littman for kindly providing RORγt reporter mice.

References

1. Ivanov II, McKenzie BS, Zhou I, Tadokoro CE, Lepelley A, et al. (2006) The orphan nuclear receptor RORgammat directs the differentiation program of group 2 innate lymphoid cells. Cell 126: 1231–1243.

2. Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, et al. (2010) Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464: 1371–1375.

3. Eberl G, Littman DR (2003) The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer’s patches. Immunity 19: 81–90.

4. Bettelli E, Korn T, Oudina M, Kuchroo VK (2006) Induction and effector functions of TH17 cells. Nature 443: 1051–1057.

5. Zheng Y, Danilenko DM, Valdez P, Littman I, Eastham-Anderson J, et al. (2007) Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 648–651.

6. Hoegi S, Bachmann M, Schiermeier F, Geon I, Hofstetter C, et al. (2011) Protective properties of inhaled IL-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol 44: 369–376.

7. Radaeva S, Sun R, Pan LN, Hong F, Gao B (2004) Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis. IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332–1342.

8. Pan H, Hou, Radaeva S, Gao B (2004) Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-induced injury and via activation of STAT3. Cell Mol Immunol 1: 43–49.

9. Zerneczic LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, et al. (2007) Interleukin-22 but not interleukin-17 protects against acute liver inflammation. Immunity 27: 647–659.

10. Ho, Eberly I, Iannone I, Benlagha K, Lessmann F, et al. (2005) Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity 22: 705–716.

11. Bezbeda J, Hill S, Stanic AK, Van Kiel L, Joyce S (2005) Commitment toward the natural T(NKT) cell lineage occurs at the CD4(+)CD8(+) stage of thymic ontogeny. Proc Natl Acad Sci U S A 102: 5114–5119.

12. Tieg S, Hentschel J, Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90: 196–203.

13. Kaneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, et al. (2000) Augmentation of Valpha14i NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191: 105–114.

14. Gantner F, Leist M, Lohse AW, Germann PG, Tieg G (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21: 190–198.

15. Kusters S, Gantner F, Kunste G, Tieg G (1996) Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 111: 462–471.

16. Takeda K, Hayakawa Y, Van Kiel L, Matsuda H, Yagita H, et al. (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 97: 5488–5503.

17. Spits H, Di Santo JP (2011) The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 12: 21–27.

18. Eberl G, Littman DR (2004) Thymic origin of intestinal alpha-beta T cells revealed by fate mapping of RORgammat(+) cells. Science 305: 248–251.

19. Nakamoto N, Ebinuma H, Kanai T, Chau PS, Ono Y, et al. (2012) CCR9+ macrophages are required for acute liver inflammation in mouse models of hepatitis. Gastroenterology 142: 21–27.

20. Raczyński AR, Muthupalani S, Schlieper K, Fox JG, Tannenbaum SR, et al. (2012) Enteric infection with Citrobacter rodentium induces coagulative liver necrosis and hepatic inflammation prior to peak infection and colonic disease. PLoS One 7: e33099.

21. Bertolotto P (1973) Mechanisms and prevention of drug-induced liver disease. Gut 14: 332–339.

22. Voronbourg C, Moster A, Bui VL, Hernandez PP, Kiss EA, et al. (2010) Regulated expression of nuclear receptor RORgammat confers distinct functional fates to NK cell receptor-expressing RORgammat(+) innate lymphocytes. Immunity 33: 736–751.

23. Michel ML, Mendes-da-Cruz D, Keller AC, Lochner M, Schneider E, et al. (2008) Critical role of ROR-gammat in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc Natl Acad Sci U S A 105: 19845–19850.

24. Park O, Jeong WI, Wang L, Wang H, Lian XZ, et al. (2009) Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology 49: 1638–1649.

25. Tupin E, Kinjo Y, Kronenberg M (2007) The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5: 405–417.

26. Cripe IN (2009) The liver as a lymphoid organ. Annu Rev Immunol 27: 147–163.

27. Dong Z, Wei H, Sun R, Tian Z (2007) The roles of innate immune cells in liver injury and regeneration. Cell Mol Immunol 4: 241–252.

28. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, et al. (2003) CD1d-macrophages are required for acute liver inflammation in mouse models of hepatitis. J Clin Invest 112: 2084–2094.

29. Heneghan MA, McFarlane IG (2002) Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 35: 7–13.

30. Leflari F, Wang H, Park O, Zhang W, Moritoki Y, et al. (2008) Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production. Gastroenterology 137: 2125–2135 e2121–2122.

31. Nagata T, McKinley L, Peschon JJ, Akorn JF, Aujla SJ, et al. (2008) Requirement of IL-17RA in Con A induced hepatitis and negative regulation of IL-17 production in mouse T cells. J Immunol 181: 7473–7479.

Author Contributions

Edited the paper: YM CP NN HS TH HY TH. Helped conceive of and supervise the study: TH. Conceived and designed the experiments: AM TK YM NN PC HE HS TH HY TH. Performed the experiments: AM. Analyzed the data: AM TK. Contributed reagents/materials/analysis tools: AM NN PC. Wrote the paper: AM TK NN HE HY.